Evidence map›Paper›PMID 37933639›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2023

[Neutrophil-lymphocyte and platelet-lymphocyte ratios for assessing disease activity in patients with rheumatoid arthritis receiving tofacitinib treatment].

Juan Tang, Juan Chen, Guoxin Lin, Hao Zhang, Ming Gui, Nannan Li, Yihong Gu, Linjuan Luo, Jian Sun

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Juan TangDepartment of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Juan ChenDepartment of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Guoxin LinDepartment of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Hao ZhangDepartment of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Ming GuiDepartment of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Nannan LiDepartment of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Yihong GuDepartment of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Linjuan LuoDepartment of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Jian SunDepartment of Nephrology and Rheumatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the value of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for assessing disease activity in patients with rheumatoid arthritis (RA) treated with tofacitinib.

methodsThis retrospective study was conducted among 98 RA patients in active stage treated with tofacitinib in Third Xiangya Hospital and 100 healthy control subjects from the Health Management Center of the hospital from 2019 to 2021. We collected blood samples from all the participants for measurement of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and other blood parameters 1 month before and 6 months after tofacitinib treatment. We further evaluated PLR and NLR before and after tofacitinib treatment in the RA patients, and analyzed their correlations with RA disease activity.

resultsPLR and NLR increased significantly in RA patients as compared with the healthy controls. In the RA patients, PLR and NLR were positively correlated with the levels of hs- CRP, ESR, IL- 6, Disease Activity Score of 28 joints-ESR (DAS28-ESR), anti-cyclic citrullinated peptide (CCP), and rheumatoid factor (RF) before and after tofacitinib treatment. Tofacitinib treatment for 6 months significantly decreased hs-CRP, ESR, IL-6, CCP, RF and DAS28-ESR levels in the RA patients.

conclusionNLR and PLR can be useful biomarkers for assessing disease activity in RA patients treated with tofacitinib.

Indexed as

Arthritis, RheumatoidNeutrophilsC-Reactive ProteinHumansInterleukin-6LymphocytesPiperidinesPyrimidinesRetrospective StudiesC-Reactive ProteinInterleukin-6PiperidinesPyrimidinestofacitinibneutrophil-lymphocyte ratioplatelet-lymphocyte ratiorheumatoid arthritistofacitinib

Identifiers

PMID37933639
PMCPMC10630215
OpenAlexW4388466061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.